Compare
Agenus Inc vs Adaptimmune Therapeutics PLC vs Fennec Pharmaceuticals Inc. vs Editas Medicine, Inc.
| Latest fiscal year | Agenus Inc AGEN | Adaptimmune Therapeutics PLC ADAPYLast annual report: year ended 2024-12-31 | Fennec Pharmaceuticals Inc. FENC | Editas Medicine, Inc. EDIT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2024-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $114.20M | $178.03M | $44.64M | $40.52M |
| Revenue growth (YoY) | +10.4% | +195.3% | -6.1% | +25.4% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | -17.7% | -38.6% | -14.1% | -394.9% |
| Net margin | -2.7% | -39.8% | -21.8% | -395.0% |
| Net income | -$3.08M | -$70.81M | -$9.74M | -$160.06M |
| EPS (Diluted) | $0.00 | -$0.05 | -$0.34 | -$1.80 |
| Operating cash flow | -$77.19M | -$73.21M | -$12.47M | -$165.24M |
| Free cash flow | -$77.20M | -$74.09M | n/a | -$165.85M |
| Cash & equivalents | $3.00M | $91.14M | $36.79M | $146.65M |
| Total assets | $226.80M | $245.96M | $70.55M | $186.53M |
| Total liabilities | n/a | $234.11M | $35.08M | $159.25M |
| Shareholders' equity | -$271.11M | $11.85M | $35.47M | $27.29M |
| Return on year-end equity | n/a | -597.6% | -27.5% | -586.6% |
| Shares outstanding | 35.32M | 1.54B | 34.16M | 97.87M |
Revenue, most recent five fiscal years
| Fiscal year | Agenus Inc | Adaptimmune Therapeutics PLC | Fennec Pharmaceuticals Inc. | Editas Medicine, Inc. |
|---|---|---|---|---|
| Latest | $114.20M Ended 2025-12-31 | $178.03M Ended 2024-12-31 | $44.64M Ended 2025-12-31 | $40.52M Ended 2025-12-31 |
| 1 year earlier | $103.46M Ended 2024-12-31 | $60.28M Ended 2023-12-31 | $47.54M Ended 2024-12-31 | $32.31M Ended 2024-12-31 |
| 2 years earlier | $156.31M Ended 2023-12-31 | $27.15M Ended 2022-12-31 | $21.25M Ended 2023-12-31 | $78.12M Ended 2023-12-31 |
| 3 years earlier | $98.02M Ended 2022-12-31 | $6.15M Ended 2021-12-31 | $1.53M Ended 2022-12-31 | $19.71M Ended 2022-12-31 |
| 4 years earlier | $295.67M Ended 2021-12-31 | $3.96M Ended 2020-12-31 | n/a | $25.54M Ended 2021-12-31 |